Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.900
-0.040 (-2.06%)
At close: Dec 5, 2025, 4:00 PM EST
1.895
-0.005 (-0.29%)
After-hours: Dec 5, 2025, 7:36 PM EST
Caribou Biosciences Revenue
Caribou Biosciences had revenue of $2.20M in the quarter ending September 30, 2025, with 8.60% growth. This brings the company's revenue in the last twelve months to $9.30M, down -19.00% year-over-year. In the year 2024, Caribou Biosciences had annual revenue of $9.99M, down -71.01%.
Revenue (ttm)
$9.30M
Revenue Growth
-19.00%
P/S Ratio
18.92
Revenue / Employee
$63,231
Employees
147
Market Cap
177.59M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CRBU News
- 5 days ago - Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 - GlobeNewsWire
- 24 days ago - Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Caribou Biosciences to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today> - Benzinga
- 4 weeks ago - Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma - GlobeNewsWire
- 4 weeks ago - Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - GlobeNewsWire
- 4 weeks ago - Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - GlobeNewsWire
- 3 months ago - Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference - GlobeNewsWire